Podcasts about wegovy

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45]; Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45]; How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15]; Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30]; Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15]; The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00]; Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45]; Why lean mass measurements are an imperfect proxy for muscle health and function [21:45]; The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00]; Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00]; Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00]; Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45]; Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00]; Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00]; Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45]; Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15]; Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00]; The risks of using gray-market retatrutide before FDA approval [52:15]; Key takeaways [54:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

More Americans are using GLP-1 drugs, like Ozempic and Wegovy, for weight loss, and that's impacting their grocery shopping habits. A new survey finds that GLP-1 use could shave up to 2.7% off grocery store sales this year. So, how are food companies adapting? Also on the program: a preview of major Supreme Court decisions coming up and a frank conversation about the costs of being in a wedding party, courtesy of the Marketplace podcast "This Is Uncomfortable."Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace Morning Report is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.Stories featured in this episode:Would you go broke for a bachelorette?

It's Episode 22 of Season 24. Enter the dark waters of the Cape Fear River as we present tales about diabolical distractions."Please, No Smoking" by Sam Conn Pantle (Story starts around 00:03:50)Produced by Jeff ClementCast: Eddie - James Solis, Casey - Dan Zappulla"The Extra Ones" by Don Tobin (Story starts around 00:19:35)Produced by Claudius MooreCast: Albert - Graham Rowat, Mrs. Holloway - Mary Murphy, Man - Peter Lewis"Debunked" by Quincy Lee (Story starts around 00:44:10)TRIGGER WARNING!Produced by Jesse CornettCast: Max - Erin Lillis, Pete - Jesse Cornett, Nathan - Atticus Jackson, Woman - Linsay Rousseau, Sarah - Nichole Goodnight"The Doll" by Joseph Yenkavitch (Story starts around 01:16:00)Produced by Phil MichalskiCast: Narrator - Tanja Milojevic, Mom - Sarah Ruth Thomas, Girl - Nichole Goodnight"The Early Bus" by Liam Rose Philipson (Story starts around 01:50:00)TRIGGER WARNING!Produced by Phil MichalskiCast: Narrator - Jeff Clement, Jake - Matthew Bradford, Carlos - Dan Zappulla, Daniel - Kyle Akers, Big Kid #1 - Atticus Jackson, Big Kid #2 - Elie Hirschman, Mister Critter - Mike DelGaudio, Driver - Peter LewisThis episode is sponsored by:Home Chef - Home Chef's meal kits are rated #1 in quality, convenience, value, taste, and recipe ease. Head to homechef.com/nosleep to get 50% off and free shipping for your first box plus free dessert for life!Betterhelp - This episode is sponsored by BetterHelp. Take a step towards a better you. Our listeners get 10% off their first month at betterhelp.com/nosleep.Weight Loss by Hims - Ready to reach your weight loss goals? Weight Loss by Hims and WegovyÆ. Get a personalized, affordable plan that gets you. Go to Hims.com/nosleep.Click here to learn more about The NoSleep Podcast teamClick here to learn more about Quincy Lee Executive Producer & Host: David CummingsMusical score composed by: Brandon Boone"The Early Bus" illustration courtesy of Kelly TurnbullThe NoSleep Podcast is Human-made for Human Minds. No generative AI is used in any aspect of work.Audio program ©2026 - Creative Reason Media - The copyrights for each story are held by the respective authors. No duplication or reproduction of this audio program is permitted without the written consent of Creative Reason Media. No part of this audio program may be used or reproduced in any manner for the purpose of training artificial intelligence technologies or systems. All rights reserved.

COME JOIN HARLOFF, ELLIS AND STERGER FOR A NIGHT OF COMEDY - THURSDAY, 10/8 @ 7:30PM SHOW HOSTED BY:  KYLE LEWIS  https://brokerage.govs.com/shows/376674 Kristian Harloff breaks down the biggest movie news stories of the day, led by a disappointing start for Supergirl at the domestic box office. Early projections have dropped to around a $39 million opening weekend, raising major questions about the future of the DCU and whether James Gunn's momentum has hit its first major roadblock. Kristian examines the numbers, audience reception, and what this could mean for DC Studios moving forward. Plus, Christopher Nolan's The Odyssey is reportedly skipping influencer screenings, DC Studios officially unveils new animated series including Absolute Batman, Joker: Laugh Riot, and Krypto, James Gunn faces fresh criticism after fans point out a Rick Flag Sr. continuity mistake, and Pixar fans may be disappointed to hear that Ratatouille 2 isn't expected anytime soon. Stories For Today: * Supergirl Off To Sluggish Start At The U.S. Box Office As Opening Weekend Projections Plummet To $39M * The Odyssey To Skip Influencer Screenings * DC Studios Announces Absolute Batman, Joker: Laugh Riot, And Krypto TV Shows At Annecy * James Gunn's Bad Week Gets Worse As Fans Roast DC Studios Boss For Rick Flag Sr. Mistake * Don't Expect A Ratatouille Sequel If you're a fan of DC Studios, Supergirl, James Gunn, Batman, Joker, Krypto, Christopher Nolan, Pixar, Marvel, or the latest movie news, this episode is for you. #Supergirl #DCU #JamesGunn #DCStudios #AbsoluteBatman #Batman #Joker #Krypto #TheOdyssey #ChristopherNolan #Ratatouille #Pixar #BoxOffice #MovieNews #KristianHarloffShow #DCComics #Hollywood #EntertainmentNews 00:00 Intro & Opening Banter  05:51 Supergirl Lower Tracking At 39 Million. 21:33 Hims & Cash App 28:23 No Odyssey For Influencers Says Christopher Nolan 41:20 DC Studios Announces Absolute Batman, Joker Laugh Riot, & Krypto TV Series. 52:52 DC Fans vs James Gunn over Rick Flagg 1:03:24 Next Pixar Sequel? Ratatouille is NOT it 1:08:25 New Spider-Man: Brand New Day Pic Released 1:11:14 Pixar Game - Wall-E, Inside Out, Finding Nemo, Cars, Incredibles etc. 1:18:01 Q&A SPONSORS: HIMS:  Ready to reach your goals? Visit https://www.hims.com/KRISTIAN to get a personalized, affordable plan that gets you. - Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hims is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A.S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.hims.com CASHAPP: Download Cash App Today: https://capl.onelink.me/vFut/76rlxe00 #CashAppPod Cash App is a financial services platform, not a bank. Banking services provided by Cash App's bank partner(s). Prepaid debit cards issued by Sutton Bank, Member FDIC. Cash App Visa® Debit Flex Cards issued by Sutton Bank, Member FDIC, and The Bancorp Bank, N.A., pursuant to a license from Visa U.S.A. Inc. See terms and conditions for the Sutton prepaid card, Sutton debit flex card, and Bancorp debit flex card. Cash App Green features, Savings, Direct deposit, Round ups, Overdraft coverage and Discounts provided by Cash App, a Block, Inc. brand. Visit cash.app/legal/podcast for full disclosures.

COME JOIN HARLOFF, ELLIS AND STERGER FOR A NIGHT OF COMEDY - THURSDAY, 10/8 @ 7:30PM SHOW HOSTED BY:  KYLE LEWIS  https://brokerage.govs.com/shows/376674 Kristian Harloff breaks down the biggest movie and entertainment stories of the day, including growing debate within the DC fan community following Supergirl's mixed reviews. Are some fans starting to lose faith in James Gunn's long-term DCU plan? Kristian discusses the resurfaced praise for the Supergirl script, the reaction from audiences and critics, and what this means for the future of DC Studios. Plus, DC Studios has officially announced new animated projects including Absolute Batman, Joker: Laugh Riot, and Krypto. However, the news has sparked confusion among fans after James Gunn previously stated that animation would be connected to the larger DCU. Kristian breaks down what these announcements could mean and whether DC's animated strategy is changing. The show also covers reports that Zendaya has held discussions about joining the Bourne franchise and Disney's Infinity Vision premium theater format generating major interest from exhibitors worldwide. Stories For Today: * Are DC Fans Losing Faith In James Gunn? "Incredible" Supergirl Script Praise Resurfaces Amid Mixed Reviews * DC Studios Announces Absolute Batman, Joker: Laugh Riot, And Krypto TV Shows At Annecy * Zendaya Has Had Talks About Bourne? * 7,500 Cinemas Apply For Disney's Infinity Vision Today's show dives into the ongoing conversation surrounding Supergirl and the DCU as fans debate whether mixed reactions to the latest film should be a cause for concern. Kristian also explores the implications of DC Studios' newly announced animated projects and whether they align with James Gunn's previously stated vision of a connected universe across film, television, animation, and games. If you're a fan of DC Studios, James Gunn, Batman, Joker, Krypto, Supergirl, Zendaya, Bourne, Disney, or the latest movie news, this episode is for you. #DCU #JamesGunn #Supergirl #DCStudios #AbsoluteBatman #Batman #JokerLaughRiot #Krypto #Zendaya #Bourne #Disney #InfinityVision #MovieNews #KristianHarloffShow #DCComics #Animation #Superman #EntertainmentNews #hollywood  SPONSORS: HIMS:  Ready to reach your goals? Visit https://www.hims.com/KRISTIAN to get a personalized, affordable plan that gets you. - Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hims is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A.S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.hims.com CASHAPP: Download Cash App Today: https://capl.onelink.me/vFut/76rlxe00 #CashAppPod Cash App is a financial services platform, not a bank. Banking services provided by Cash App's bank partner(s). Prepaid debit cards issued by Sutton Bank, Member FDIC. Cash App Visa® Debit Flex Cards issued by Sutton Bank, Member FDIC, and The Bancorp Bank, N.A., pursuant to a license from Visa U.S.A. Inc. See terms and conditions for the Sutton prepaid card, Sutton debit flex card, and Bancorp debit flex card. Cash App Green features, Savings, Direct deposit, Round ups, Overdraft coverage and Discounts provided by Cash App, a Block, Inc. brand. Visit cash.app/legal/podcast for full disclosures.

How quickly can you improve your gut health? Can diet help lower your risk of dementia? And what should you know about food labels and healthy weight loss? In this special live Q&A, Prof Tim Spector, Prof Sarah Berry and Dr Federica Amati answer your biggest nutrition questions and share practical, evidence-based advice you can use today. Drawing on decades of research and data from hundreds of thousands of people, they explain how diet can influence the gut microbiome, brain health, hunger, energy levels and long-term health. They discuss dementia risk, healthy snacking, intermittent fasting, ultra-processed foods, plant diversity, breakfast, food labels and the latest science on weight loss. You'll learn how quickly the gut microbiome may respond to dietary change, why some foods keep you fuller for longer, how to build a healthier breakfast, and simple ways to make better food choices. The team also explain why small dietary changes can have lasting benefits. If your daily food choices influence your gut health, brain health and future wellbeing, which change is worth making first?

Love island obsessed Kevin and his lady Marcelle try to make Whitney like something popular and it goes perfectly weirdly. Whitney tries to figure out the physiological profile of each contestant based on their photos alone, and we dissect this new form of emotion porn and that reality tv may just be mama for women Tickets for The Big Baby Tour https://www.whitneycummings.com SHOP: https://whitneycummings.com/index.html#store Thank you to our sponsors! Square #ad Get up to $200 off Square hardware when you sign up at https://square.com/go/WHITNEY! #squarepod Jones Road Beauty #ad Use code GOODFORYOU at https://www.jonesroadbeauty.com to get a Free Gift with your first purchase! #JonesRoadBeauty #ad OLIPOP #ad Get a free can of OLIPOP: buy any 2 cans of OLIPOP in store, and they'll pay you back for one. Works on single cans of any flavor, any retailer. Get yours at https://drinkolipop.com/WHITNEY. OLIPOP is available in the soda aisle and with the chilled beverages at thousands of retailers nationwide, including Walmart and Target. Hers #ad Ready to reach your goals? Visit https://www.forhers.com/whitney to get personalized, affordable care that gets you. That's F-O-R-H-E-R-S dot com slash whitney forhers.com slash whitney Weight Loss by Hers is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.forhers.com. Bellesa EVERYONE who signs up wins a FREE toy or gift card! https://www.shopbboutique.co/vibe/goodforyou-yt

COME JOIN HARLOFF, ELLIS AND STERGER FOR A NIGHT OF COMEDY - THURSDAY, 10/8 @ 7:30PM SHOW HOSTED BY:  KYLE LEWIS  https://brokerage.govs.com/shows/376674 Kristian Harloff breaks down the biggest movie news stories of the day, led by his full Supergirl review! With Milly Alcock officially making her mark on the DCU, Kristian shares his thoughts on the film, its place in James Gunn's evolving universe, and whether Supergirl can build on the momentum established by Superman and the early DC Studios slate. Plus, new reports reveal that Milly Alcock's Supergirl will play a major role in the next DCU movie after Man of Tomorrow, while producers discuss the relationship between DC Studios and incoming Paramount owner David Ellison. The show also covers major horror news as It Follows filmmaker David Robert Mitchell is set to write Freddy's 3, and updates on the upcoming projects Homewreckers and School Bus. Today's episode focuses heavily on Supergirl as Kristian reviews the film and discusses what its future means for the larger DCU. With new comments confirming that Milly Alcock's Kara Zor-El will have a significant role moving forward, the foundation for DC's next chapter is becoming clearer. The show also explores the latest horror movie developments, including Freddy's 3 landing a notable writer, and discusses how DC Studios may continue operating under a changing Hollywood landscape. If you're a fan of Supergirl, Superman, DCU, James Gunn, Milly Alcock, Freddy's, horror movies, or the latest movie news, this episode is for you. SPONSORS: HIMS:  Ready to reach your goals? Visit https://www.hims.com/KRISTIAN to get a personalized, affordable plan that gets you. - Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hims is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A.S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.hims.com CASHAPP: Download Cash App Today: https://capl.onelink.me/vFut/76rlxe00 #CashAppPod Cash App is a financial services platform, not a bank. Banking services provided by Cash App's bank partner(s). Prepaid debit cards issued by Sutton Bank, Member FDIC. Cash App Visa® Debit Flex Cards issued by Sutton Bank, Member FDIC, and The Bancorp Bank, N.A., pursuant to a license from Visa U.S.A. Inc. See terms and conditions for the Sutton prepaid card, Sutton debit flex card, and Bancorp debit flex card. Cash App Green features, Savings, Direct deposit, Round ups, Overdraft coverage and Discounts provided by Cash App, a Block, Inc. brand. Visit cash.app/legal/podcast for full disclosures.

Starting July 1, Medicare will begin a new pilot program that will allow some users to access popular GLP-1 weight-loss medications at a reduced cost. Originally developed to treat diabetes, GLP-1 medications like Wegovy have exploded in popularity. Dr. Carolyn Bramante is an associate professor at the University of Minnesota Medical School who specializes in obesity and weight loss. She joined MPR News host Nina Moini to talk about how GLP-1 drugs have changed medicine and what broader access for older Americans could mean.

Grace from "Moonlight Should Be Beautiful" is back for the conclusion of her heartbreaking secret.  In part one she revealed the dark secret of a rape she suffered at the age of 15 that led to a secret abortion.  In part two, she is forced to confront the ramifications of that decision as an adult when she gets an unexpected diagnosis.  HERS Thank you, HERS!  forhers.com/SECRET for your personalized, affordable care that gets you. That's F-O-R-H-E-R-S dot com slash secret. forhers.com slash secret. Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hers is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A/S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit forhers.com. HOME CHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life!  HomeChef.com/SECRET.  Must be an active subscriber to receive free dessert. HOMESERVE For 50% less your first year, go to HomeServe.com/secret. Void in Florida. MINT MOBILE Make the switch! MINTMOBILE.com/SECRET   PICTURES See Grace, her husband and her mom on social right now. They are waiting for you on Threads, Facebook, Instagram and X.  Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED Grace returns in one week to tell Susie about a time years later she heard from the twin.  You will not believe your ears.  That and other updates, like what was going on with Grace's sister that held her back from revealing all to mom. Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See all our sponsors past and present, and their offers, many of which are still valid: secretroompodcast.com/codes  FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page!  Just ask to join, all are welcome. :) YOUR SECRET  Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!

COME JOIN HARLOFF, ELLIS AND STERGER FOR A NIGHT OF COMEDY - THURSDAY, 10/8 @ 7:30PM SHOW HOSTED BY:  KYLE LEWIS  https://brokerage.govs.com/shows/376674 Kristian Harloff breaks down the biggest movie and TV stories of the day, including his full Supergirl review! DC Studios' latest entry has finally arrived, and Kristian shares his thoughts on Milly Alcock's performance, the future of the DCU, James Gunn's vision, and whether Supergirl lives up to the hype following Superman's success. Plus, Toy Story 5 is off to a massive start with a $312 million global box office debut, proving Pixar is still a major force at the movies. Meanwhile, Spider-Man: Brand New Day continues to shatter expectations with advance ticket sales now suggesting a potential $250 million+ opening weekend. Kristian also reviews the latest episode of House of the Dragon and breaks down the biggest moments from the hit HBO fantasy series. Stories For Today: * Supergirl Review * Toy Story 5 Has $312 Million Global Start * New Spider-Man Pre-Sales Suggest $250M+ Start * House Of The Dragon Review Today's episode is packed with major franchise discussion as Kristian reviews Supergirl, analyzes Toy Story 5's huge opening weekend, and looks at whether Spider-Man: Brand New Day is headed for one of the biggest superhero debuts ever. The show also features a House of the Dragon review, covering the biggest twists, performances, and what could be coming next in the battle for the Iron Throne. If you're a fan of Supergirl, Superman, DCU, Marvel, Spider-Man, MCU, Toy Story, Pixar, House of the Dragon, Game of Thrones, or the latest movie news, this episode is for you. #Supergirl #DCU #JamesGunn #MillyAlcock #Superman #SpiderManBrandNewDay #SpiderMan #TomHolland #Marvel #MCU #ToyStory5 #Pixar #HouseOfTheDragon #GameOfThrones #BoxOffice #MovieNews #KristianHarloffShow #DCStudios #EntertainmentNews #HBO SPONSORS: HIMS:  Ready to reach your goals? Visit https://www.hims.com/KRISTIAN to get a personalized, affordable plan that gets you. - Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hims is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A.S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.hims.com CASHAPP: Download Cash App Today: https://capl.onelink.me/vFut/76rlxe00 #CashAppPod Cash App is a financial services platform, not a bank. Banking services provided by Cash App's bank partner(s). Prepaid debit cards issued by Sutton Bank, Member FDIC. Cash App Visa® Debit Flex Cards issued by Sutton Bank, Member FDIC, and The Bancorp Bank, N.A., pursuant to a license from Visa U.S.A. Inc. See terms and conditions for the Sutton prepaid card, Sutton debit flex card, and Bancorp debit flex card. Cash App Green features, Savings, Direct deposit, Round ups, Overdraft coverage and Discounts provided by Cash App, a Block, Inc. brand. Visit cash.app/legal/podcast for full disclosures.

GLP-1 drugs such as Ozempic and Wegovy have been linked to serious vision concerns, including diabetic retinopathy and optic nerve damage that can result in lasting vision loss Research suggests the highest risk of sudden vision loss may occur within the first year of starting these drugs, with symptoms sometimes appearing overnight without pain or warning Case reports document that even healthy adults using GLP-1 drugs for weight loss — with no history of diabetes or eye disease — have experienced lasting vision loss Sudden changes in vision such as blurriness, blind spots, or loss of color perception may be early warning signs of optic nerve damage. Recognizing them quickly can support timely evaluation and care Lifestyle approaches such as reducing vegetable oils, choosing the right carbs, and supporting gut microbes may help support healthy metabolism

(June 23, 2026) Battle over single-use plastics erupts as 17 states move to block California law. California union warns of mass exodus with Newsom’s return to office order. World Cup fans from around the world are wowed by the United States. When diets don’t work: Parents turn to Wegovy for elementary school kids.See omnystudio.com/listener for privacy information.

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode of On The Pen, Dave Knapp sits down with obesity medicine expert Angela Fitch to break down exactly who qualifies, how to apply, which medications are covered, and what this historic expansion of obesity treatment access means for patients across America.We discuss:✅ Medicare Bridge Program eligibility requirements✅ Zepbound, Wegovy, Foundayo (orforglipron), and GLP-1 coverage updates✅ BMI and comorbidity qualifications✅ Prediabetes, sleep apnea, cardiovascular disease, and obesity treatment access✅ How Medicare patients can obtain GLP-1 medications✅ Why obesity is finally being treated as a chronic disease✅ The future of obesity medicine and Medicare coverage✅ Concerns about access to care vs access to medication✅ Muscle loss, nutrition, strength training, and healthy weight loss✅ The Treat and Reduce Obesity Act (TROA)This may be one of the most important developments in obesity treatment history, potentially opening the door for millions of Americans living with obesity, prediabetes, cardiovascular disease, and other weight-related conditions to receive evidence-based care.

Thanks for Grüns for sponsoring this video! Get up to 52% off! Just click here https://gruns.yt.link/imtCLv1. Today's show features Kristian's full reaction of Supergirl as the DCU's next major chapter arrives in theaters. The episode also examines whether Toy Story 5 is on its way to becoming Pixar's next billion-dollar hit and if Spider-Man: Brand New Day is poised for one of the biggest superhero openings of all time. On top of that, Kristian breaks down the latest House of the Dragon episode and discusses where the hit fantasy series is headed next. If you're a fan of Supergirl, DCU, Superman, Spider-Man, Marvel, MCU, Toy Story, Pixar, House of the Dragon, Game of Thrones, or the latest movie news, this episode is for you. SPONSORS: HIMS:  Ready to reach your goals? Visit https://www.hims.com/KRISTIAN to get a personalized, affordable plan that gets you. - Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hims is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A.S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.hims.com CASHAPP: Download Cash App Today: https://capl.onelink.me/vFut/76rlxe00 #CashAppPod Cash App is a financial services platform, not a bank. Banking services provided by Cash App's bank partner(s). Prepaid debit cards issued by Sutton Bank, Member FDIC. Cash App Visa® Debit Flex Cards issued by Sutton Bank, Member FDIC, and The Bancorp Bank, N.A., pursuant to a license from Visa U.S.A. Inc. See terms and conditions for the Sutton prepaid card, Sutton debit flex card, and Bancorp debit flex card. Cash App Green features, Savings, Direct deposit, Round ups, Overdraft coverage and Discounts provided by Cash App, a Block, Inc. brand. Visit cash.app/legal/podcast for full disclosures.

Why aren't there more medical insurance plans that cover alternative medicine? Solutions for Long Covid; MK7 vitamin K slows arterial calcification; Keto diet shows promise for treatment of anorexia; It's not so much salt restriction—it's the dietary sodium/potassium ratio in hypertension; Study finds multivitamins don't keep you from getting Covid—but when you get it, it's milder; Incidence of social anxiety disorder is soaring among young people.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)What if Medicare finally made GLP-1 medications for weight management more affordable — could this be the moment that changes access for millions of people?Today, we're talking about something that's been years in the making in the world of obesity care: the expanded coverage of anti-obesity medications for patients on Medicare. Starting July 1st, eligible Medicare beneficiaries have a real opportunity to access GLP-1 receptor agonist medications at a much more affordable monthly cost through a new federal program — and for many patients, this could mark a major shift in access to treatment that's historically been limited or completely out of reach under Medicare's coverage rules.This change didn't happen overnight. It comes after years of advocacy, policy discussions, and ongoing efforts to get obesity recognized as a chronic medical condition that deserves treatment just like any other disease. In this episode, we break down where this program came from, how it connects to the bigger picture of obesity care, who it applies to, and everything you need to know about eligibility, covered medications, and how the process actually plays out in real life.Topics discussed:How the Bridge Program Could Expand Access to Obesity MedicationsFor the First Time, Medicare Is Opening the Door to Obesity MedicationsThe BMI and Health Condition CriteriaWhy the Reason for Your Prescription Matters Just as MuchThe Details That Make a Real Difference — Prior BMI and Lifestyle SupportThe List of Weight Loss Medications Covered by the Bridge ProgramWant the full breakdown? This episode covers all the details on eligibility, covered medications, and what this program could mean for you or someone you love navigating Medicare and obesity treatment. Find it wherever you get your podcasts — and if it helps, share it with someone who might need to hear it too.Resources mentioned in this episode:GLP-1 Prescribers Guide — CMSMedicare GLP-1 Bridge Program Details — CMSConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

If I could go back and start my GLP-1 journey all over again, there are a lot of things I would do differently.Not because I regret taking a GLP-1—but because there were lessons I had to learn through experience that I wish someone had told me from the very beginning.In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 user Gianna Beasley shares the biggest things she wishes she knew before starting Ozempic, Wegovy, Mounjaro, and GLP-1 medications, including the nutrition, mindset, and lifestyle lessons that made the biggest difference.We're covering:The mistakes I made early in my GLP-1 journeyWhy protein matters more than most people realizeThe importance of hydration and side effect managementWhy I wish I focused less on the scale and more on strengthThe mental health and mindset work I wish I had done soonerWhy comparison is one of the fastest ways to sabotage your progressWhat actually matters for long-term success on a GLP-1The advice I would give myself if I were starting over todayWhether you're considering a GLP-1, just getting started, or have been taking one for a while, this episode will help you avoid common pitfalls and focus on what truly supports your health and success.

What is GLP-1 microdosing, and can smaller doses of medications like Ozempic, Wegovy, and Zepbound lead to better long-term weight loss results?In this episode, registered dietitian Zoe is joined by Deidre, FNP, to break down one of the biggest conversations in obesity medicine right now: GLP-1 microdosing. They explain how microdosing differs from standard manufacturer dosing, why FDA-approved dosing schedules are designed for clinical trials, and why a one-size-fits-all approach may not work for every patient.Deidre explains how slower, smaller dose increases may help reduce side effects like nausea and abdominal discomfort, while still supporting hunger control, fewer cravings, less food noise, and gradual weight loss. They also discuss super responders, non-responders, compounded medications, and why personalized GLP-1 dosing can make a major difference in long-term maintenance.They also unpack the debate around GLP-1 microdose marketing, including the recent dispute involving Eli Lilly, Noom, and tirzepatide, and what it means for patients navigating telehealth weight loss programs.Most importantly, Zoe and Deidre explain why medications are only one part of obesity treatment. Sustainable weight loss still depends on nutrition, whole foods, protein, fiber, lifestyle changes, and long-term support.

ABC's Jim Ryan joins Arizona’s Morning News to talk about the new black market for next-gen diet drugs like Wegovy and Zepbound. People are so eager to try them that they’ll jump the gun on FDA approvals. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve, with significant scientific advancements, regulatory updates, and strategic business moves shaping the landscape. Let's delve into these developments, starting with some key insights from oncology. In the realm of oncology, minimal residual disease (MRD) is becoming increasingly pivotal. Tumor-informed MRD is being leveraged to design more intelligent trials and interpret early responses, aiding in navigating developmental risks more effectively. This approach was a focal point of discussions at the American Society of Clinical Oncology's annual meeting, where experts emphasized the need to translate precision oncology discoveries into patient care, aiming to surmount existing challenges. The focus on MRD in oncology could lead to earlier detection of treatment responses and personalized therapeutic approaches. Verastem Oncology recently revisited its strategy concerning its combination treatment of avutometinib plus defactinib for metastatic pancreatic cancer. While clinical trials produced moderate results, the company is now redirecting focus toward other promising candidates in its pipeline. Similarly, Novocure faced setbacks as its tumor-treating electric fields device did not achieve its primary endpoint in a Phase 3 glioblastoma trial. These outcomes highlight the persistent challenges in tackling aggressive brain cancers. On the regulatory front, Spero Therapeutics achieved a significant milestone with FDA approval for Utebzi to treat complicated urinary tract infections. This approval marks a turnaround from a previous rejection four years ago, facilitated through a partnership with GSK. Meanwhile, in Europe, Cinnagen secured approval for Zandoriah, a biosimilar of teriparatide, to treat osteoporosis in adults—a testament to their investment in infrastructure and manufacturing capabilities. The industry also sees growing interest in cell therapy automation, with companies like Cellares and Ori Biotech leading the charge. These advancements reflect an industry-wide push towards more efficient manufacturing processes for cell therapies. In metabolic health, Novo Nordisk's oral GLP-1 drug Wegovy has gained significant traction due to its brand familiarity among healthcare providers, crucial in its competition with Eli Lilly's Foundayo. Market trends reveal competitive dynamics within obesity treatments as Novo Nordisk's oral Wegovy outpaces Eli Lilly's offerings due to strong brand recognition. Biogen's acquisition of Raythera for $1 billion underscores its strategic intent to enhance its portfolio with promising preclinical immunology assets. Such acquisitions highlight broader industry strategies focusing on expanding pipelines through targeted investments. This move aligns with Biogen's focus on autoimmune diseases and enhances its preclinical portfolio. In business development news, LabGenius Therapeutics partnered with LG Chem to utilize AI and machine learning for designing multispecific antibodies targeting tumors. This collaboration highlights the growing importance of artificial intelligence in accelerating drug discovery processes within oncology. Clinical trials continue to yield promising results. F2G and Shionogi's antifungal small molecule olorofim demonstrated efficacy comparable to Ambisome in treating invasive aspergillosis—an advancement crucial for infectious diseases with limited treatment options. D&D Pharmatech's Zabopegdutide showed an impressive improvement rate in fibrosis during Phase 2 trials for metabolic dysfunction-associated steatohepatitis, emphasizing the potential of protein-based therapies in treating metabolic liver disorders. Corporate launches reflect strategic maneuvers aimed at advancing therapeutic developments. Innoviva introduced Nortiva Bio to focus on long-acting oral medicines using acquired platform technology from Lyndra Therapeutics—aiming to revolutionize women's health through sustained-release formulations. The financial landscape also shows active movement, exemplified by Kardigan's $400 million IPO aimed at progressing cardiovascular drugs into advanced trials. Alvotech's public offering signals a commitment to biosimilar medicines—a sector poised for growth due to rising demand for cost-effective biologic therapies. Overall, these developments reflect a robust innovation pipeline within the pharmaceutical and biotech industries as they strategically address complex diseases through novel therapies and technologies. As scientific progress accelerates alongside strategic corporate actions, these changes promise enhanced patient care outcomes through groundbreaking treatments that cater to unmet medical needs worldwide.Support the show

Ozempic, Wegovy and Mounjaro can help people lose weight. But what should you eat on GLP-1 drugs to avoid side effects, protect muscle, and maintain results long term? In this episode, Dr Federica Amati, ZOE's Head Nutritionist and author of The Appetite Reset, explains how these drugs work, why many people struggle with side effects, and why losing weight does not automatically mean better health. You'll learn why the weight lost may not be fat, why nutrient deficiencies, dehydration and muscle loss can become a risk, and what to eat before, during and after treatment. Federica shares four practical principles to help reduce side effects, protect lean mass, improve diet quality and support long-term health whether you stay on these medications or eventually stop taking them. Millions of people are now using GLP-1 drugs. But if these medications reduce appetite so effectively, how do you make sure your body still gets the nutrients it needs?

The GLP-1 conversation has completely changed the wellness world. What started as a diabetes medication is now being talked about for weight loss, metabolism, cravings, inflammation, and even longevity.But as more people jump on medications like Ozempic, Wegovy, and Mounjaro, some important questions are getting overlooked. .  .Today, we're talking about:The hidden mistake that could make your weight loss backfireWhy some people lose more than just body fat, but lean tissueThe nutrient strategy experts say becomes even more important on GLP-1 medicationsThe surprising symptom many people can blame on the medication itself (but could not be)How to protect your metabolism while losing weightNatural ways to support your body's own GLP-1 productionThe connection between your gut bacteria, appetite, and cravingsWhy sleep may be playing a bigger role than you realizePlus . . . today's feelgood thing.Big thanks to our sponsor, ITL Health.More information on their magnesium formulations, designed with bioavailability in mind, can be found here:https://itlhealth.ca/Thank you for being a part of this space! xo

SUMMARY DEL SHOW Futuros suben este jueves recuperándose de la caída de ayer, después de que la Fed mantuvo tasas sin cambios pero sorprendió con un tono más hawkish en su primera decisión bajo Kevin Warsh. $INTC sube 9% en premarket tras confirmarse que $AAPL se asocia con la compañía para fabricar chips de forma doméstica, impulsando a todo el sector de semiconductores. $QBTS avanza con un nuevo simulador de computación cuántica, mientras Wegovy oral gana terreno en las prescripciones de $NVO y $CI recorta cobertura de GLP-1 para sus empleados.

This episode explores how to use GLP-1 medications like semaglutide/Ozempic and tirzepatide/Mounjaro safely and effectively. Dr. Mike Hart and Dr. Christle Guevarra Do discuss once-weekly dosing, individualized titration, optimal dose selection, food noise, appetite suppression, and the risks of dosing mistakes with vials or gray-market peptides. They also cover why resistance training, protein, fiber, and realistic nutrition habits are essential for preserving muscle and maintaining results. The conversation expands into GLP-1 benefits beyond weight loss, including cardiovascular protection, inflammation, autoimmune flares, addiction-related behaviors, alcohol cravings, libido, menstrual cycles, PCOS, sleep apnea, and what to expect when stopping the medication. Dr. Christle Guevarra Do is a physician focused on obesity medicine, GLP-1 education, weight management, and sustainable lifestyle change. Drawing from both her clinical experience and her own long-term use of GLP-1 medication, she helps patients understand how these medications fit into the bigger picture of long-term health. Her approach emphasizes individualized care, strength training, nutrition, behavior change, and realistic maintenance strategies rather than quick fixes. In this episode, she shares practical guidance for using GLP-1s responsibly while protecting muscle, managing hunger, and building habits that support lasting results. Dr. Christle Guevarra Website https://www.drchristle.com/ Dr. Christle's Free GLP-1 Guide https://www.drchristle.com/glp1-guide Dr. Christle Instagram https://www.instagram.com/dr.christle/ Ozempic — semaglutide https://www.ozempic.com/ Wegovy — semaglutide for weight management https://www.wegovy.com/ Mounjaro — tirzepatide https://mounjaro.lilly.com/ Zepbound — tirzepatide for weight management / sleep apnea https://zepbound.lilly.com/ FDA: Concerns With Unapproved GLP-1 Drugs https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Retatrutide Clinical Trial Info https://clinicaltrials.gov/study/NCT05882045 Vyvanse — lisdexamfetamine https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad Creatine — NIH Supplement Info https://ods.od.nih.gov/factsheets/ExerciseAndAthleticPerformance-HealthProfessional/ Psyllium Husk / Fiber — MedlinePlus https://medlineplus.gov/druginfo/meds/a601104.html Berberine — NCCIH https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know Tesamorelin — MedlinePlus https://medlineplus.gov/druginfo/meds/a611035.html CJC-1295 — PubMed Research https://pubmed.ncbi.nlm.nih.gov/16352683/ Ipamorelin — PubMed Research https://pubmed.ncbi.nlm.nih.gov/9849822/ FDA: Peptides / Compounding Safety Concerns https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks Oura Ring https://ouraring.com/ White Claw https://www.whiteclaw.com/   Show Notes 00:00 Welcome to the Hart2Heart Podcast 00:45 Weekly Dosing Debate 03:41 Starting Dose Basics 06:28 Pens vs Vials Safety 08:37 Finding Your Sweet Spot 11:01 Nighttime Binge Window 13:32 Lifestyle Work Still Matters 14:30 Benefits Beyond Weight 17:27 Libido and Low Calories 22:26 Alcohol Hits Different 24:59 Cancer Claims Reality Check 26:59 Strength Training Priority 29:06 Supplements and Creatine 29:38 Creatine Protein Fiber Basics 31:50 Berberine Pros and Cons 32:37 Peptides Sleep and Muscle 35:28 Too Lean for GLP-1 38:52 Cycles PCOS and Fertility 40:45 Food Noise vs Appetite 44:42 Staying On or Stopping 49:19 Heart Rate and HRV Concerns 51:38 Ozempic vs Mounjaro Choices 54:45 Sleep Apnea and Wrap Up The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

GLP-1 agonists, like semaglutide (brand names Ozempic and Wegovy), are peptides that mimic this natural hormone. They're typically used for managing type 2 diabetes and, more recently, for weight loss. These peptides work by enhancing insulin secretion when glucose levels are elevated, slowing down gastric emptying, and reducing appetite. They also help lower blood pressure and stabilize blood sugar and cholesterol levels. Most recently they've been approved for improving cardiovascular health.  Read the Full Episode Transcript: https://pepties.com/glp-1-microdosing/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Buy Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers. The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in mergers and acquisitions. A recent analysis by PwC reports that M&A activity has reached over $65 billion in deal value during the first quarter of 2026, marking the strongest quarter since 2020. This uptick underscores a robust confidence within the industry, with companies strategically leveraging these mergers to bolster their pipelines and explore new therapeutic territories. Eli Lilly's acquisition of non-opioid pain drugmaker 4E is a case in point, as it reflects a broader industry shift towards precision medicine and non-opioid pain management solutions—a response to growing concerns over opioid addiction. On the regulatory front, notable developments include Colorado's drug import plan receiving FDA approval. This marks a bold step in curbing drug costs across the U.S., although implementation challenges remain due to complex logistical and regulatory landscapes. Meanwhile, Novo Nordisk is expanding its global manufacturing footprint with a new plant in the Czech Republic for diabetes and obesity drugs, alongside a $29 million investment to upgrade its Chinese facility. This expansion aligns with Novo's strategic preparation to seek Chinese regulatory approval for its Wegovy pill, potentially transforming the obesity treatment landscape. In a move that could reshape vaccine development, Moderna is advancing its mRNA-based influenza vaccine candidate through regulatory channels. The FDA's favorable reviews ahead of an advisory committee meeting highlight the growing acceptance of mRNA technology beyond COVID-19 vaccines. This technology holds promise for transforming vaccine development across various infectious diseases. Precision oncology continues to grapple with translating scientific discoveries into practical applications that genuinely improve patient outcomes. The ASCO 2026 conference emphasized this critical transition from discovery to implementation as essential for advancing precision medicine. Turning to gene therapy, UniQure is preparing for a significant milestone—submitting an accelerated Biologics License Application for its Huntington's disease therapy. This follows a reversal by the FDA, which now considers UniQure's Phase 1/2 trial data sufficient for submission. Should this therapy gain approval, it would be groundbreaking as the first genetic medicine for Huntington's disease, setting a precedent for future gene therapies targeting other genetic disorders. In another strategic partnership, Jazz Pharmaceuticals has teamed up with AbCellera to develop T-cell-engaging antibodies for oncology indications, illustrating the potential financial rewards associated with innovative cancer therapies. This collaboration could yield up to $820 million per program and highlights how partnerships are crucial in expediting drug development timelines. These stories reflect broader industry trends emphasizing innovation and strategic partnerships while navigating complex regulatory landscapes. The focus on precision medicine and advanced biologics continues to drive scientific advancements, with companies like Vedana Therapeutics targeting unmet needs in neurology through novel therapeutic approaches. Meanwhile, international collaboration is gaining traction in regulatory processes. The newly launched transatlantic liaison program between the FDA and MHRA aims to accelerate drug approvals and foster innovation across borders—an initiative that underscores the importance of collaborative frameworks. However, not all news is optimistic. Be Biopharma's decision to terminate its hemophilia B cell therapy trial highlights the challenges companies face in competitive therapeutic areas. Despite previous optimism, similar withdrawals by Pfizer and BioMarin indicate the necessity for robust clinical data and clear market differentiation strategies. Furthermore, Merck's recent agreement with Protillion Technologies marks an increased focus on integrating artificial intelligence into drug discovery processes—a trend promising accelerated timelines and improved trial success rates. As these developments unfold, it's evident that the pharmaceutical and biotech sectors are at an intersection where scientific innovation meets strategic business decisions. The potential approval of UniQure's gene therapy could catalyze further advancements in genetic medicine—while M&A activities suggest an industry poised for transformative growth. For stakeholders—from researchers to executives—the ability to adapt to these dynamic changes will be crucial in shaping the future of drug development and patient care. In conclusion, these stories collectively paint a picture of an industry evolving through scientific breakthroughs while adapting through strategic business decisions. As new technologies integrate into this space alongside regulatory advancements in gene therapy, this period of transformation holds promising implications for addressing unmet medical needs and enhancing therapeutic outcomes globally.Support the show

¿La metformina sirve para bajar de peso? ¿Es un tratamiento para toda la vida? ¿Y qué diferencia tiene con medicamentos como Ozempic, Wegovy o Mounjaro? En este episodio hablamos sobre qué es la metformina, cómo funciona realmente dentro del cuerpo, quiénes podrían beneficiarse de su uso y cuáles son sus efectos secundarios más frecuentes. También aclaramos algunas de las dudas más comunes sobre resistencia a la insulina, prediabetes, diabetes tipo 2 y pérdida de peso, además de revisar cuándo puede ser una herramienta útil y cuándo no necesariamente es la mejor opción. Si actualmente utilizas metformina o te la han recomendado recientemente, este episodio te ayudará a entender qué sí puedes esperar de este medicamento y qué aspectos vale la pena revisar para acompañar mejor tu tratamiento.

What Really Happens Inside an Obesity Clinic GLP-1 medications are everywhere right now. Patients are asking about Ozempic, Wegovy, Zepbound, compounded medications, muscle loss, “Ozempic face,” insurance denials, and what happens when the weight loss slows down.But what does obesity medicine actually look like inside the clinic? In this episode, I'm joined by Joseph Zucchi, PA-C, clinical supervisor and physician associate at Transition Medical Weight Loss in Salem, New Hampshire. This is not your typical GLP-1 conversation. We're going beyond protein goals, nausea tips, and constipation management to talk about what clinicians are really facing in practice: how to dose these medications, when to switch, and how to support patients when insurance coverage disappears.In this episode, you'll learn:What to assess when a patient hits a weight loss plateau beyond simply increasing the dose  How to talk with patients about GLP-1 concerns like muscle loss, thyroid cancer warnings, GI side effects, and “Ozempic face”  Why obesity medications are tools, not “cheating,” and how to address weight stigma in the exam room  What clinicians should know about compounded GLP-1 medications and why FDA-approval matters  How to document for prior authorizations and what insurance companies are often looking for  What happens when patients lose GLP-1 coverage and how to discuss alternative medication options  What Joe is most excited about in the future of obesity medicine, including new medications and expanding coverage If you prescribe GLP-1 medications, counsel patients on weight management, or feel overwhelmed by the insurance and documentation side of obesity medicine, this episode will give you a practical, behind-the-scenes look at what comprehensive obesity care can look like.Connect with JoeResources mentioned:Obesity Medicine Nutrition Course (with a 2026 medication update) Use code POD15 for 15% off!155 | Unstuck: Strategies for Sustainable Weight Loss151 | Are GLP-1s Masking Undiagnosed Eating Disorders?Obesity Medication InfographicAny Questions? Send Me a MessageSupport the showConnect with Colleen:InstagramLinkedInSign up for my FREE Newsletter - Nutrition hot-topics delivered to your inbox each week.Disclaimer: This podcast is a collection of ideas, strategies, and opinions of the author(s). Its goal is to provide useful information on each of the topics shared within. It is not intended to provide medical, health, or professional consultation or to diagnosis-specific weight or feeding challenges. The author(s) advises the reader to always consult with appropriate health, medical, and professional consultants for support for individual children and family situations. The author(s) do not take responsibility for the personal or other risks, loss, or liability incurred as a direct or indirect consequence of the application or use of information provided. All opinions stated in this podcast are my own and do not reflect the opinions of my employer. 

Former Navy SEAL Team 6 operator Craig "Sawman" Sawyer — founder of the nonprofit Veterans for Child Rescue — joins Mike Vera on the Healthy & Awake Podcast to share his firsthand assessment of child trafficking in America: how he says it operates, why he believes it stays out of the headlines, and what he argues regular people can do about it. One of the heavier conversations we've had on the show, and one of the most important.

This week it's just Steven and Devon holding down the fort while Ben is away, which means the conversation somehow manages to jump from guitar maintenance to Star Wars collectibles to post-apocalyptic murder mysteries without missing a beat. Real Life Devon spent part of the week giving some attention to an old Kelly-style guitar that had been fighting him for years. After wrestling with the floating tremolo system, he explains the joys and frustrations of guitar intonation and why getting everything properly adjusted can feel more like engineering than music. With the guitar finally behaving itself, he's been spending time learning Vivaldi's Summer, proving once again that classical music can be every bit as metal as heavy metal. Meanwhile, Steven returned from a Disney trip with a collection of souvenirs that may or may not require their own dedicated shelf. The haul includes a Spira gift card, a BB-series droid, a C-series droid head popcorn bucket, a Grand Holocron, a new Star Wars font hat, and nearly every Kyber crystal available. Unfortunately, despite collecting the entire rainbow, none of the elusive secret crystals made their way home. Such is the way of the Force. Future or Now Devon dives into Paradise on Hulu, starring Sterling K. Brown. What initially appears to be a political thriller quickly reveals itself to be something much stranger. Without spoiling too much, the series combines a whodunit mystery with a post-apocalyptic setting and some surprisingly deep character development. The show's vision of "The American Dream Underground" becomes one of the most fascinating aspects of the story, and Devon argues that the character work is what truly elevates the series above similar mystery shows. The conversation also briefly touches on Hoppers, now available on Disney+. The verdict? It's definitely strange. Whether that strangeness is good or bad may depend entirely on your tolerance for Pixar-style weirdness. There may also be connections to the Pixar Theory, but there simply isn't enough time to open that particular can of worms. Steven brings an interesting study examining the real-world effects of popular GLP-1 weight-loss medications like Ozempic, Wegovy, Mounjaro, and Zepbound. Researchers analyzing Fitbit data discovered that while patients successfully lost weight after starting the medications, many also became less physically active. Daily step counts and exercise levels declined, raising concerns because these drugs can reduce muscle mass alongside fat loss. The findings highlight an important reminder: losing weight and maintaining physical fitness aren't necessarily the same thing, and preserving strength remains a critical part of long-term health. Links Paradise (IMDb): https://www.imdb.com/title/tt27444205 Weight-loss medication activity study: https://www.sciencedaily.com/releases/2026/06/260614011841.htm   This episode covers everything from guitar maintenance and Disney loot to dystopian mysteries and the surprising relationship between weight loss and physical activity. Just another normal week on Science Faction.

You can't scroll through your feed for five seconds without seeing someone talking about Ozempic, Wegovy, or the newest GLP-1 drug.But here's what nobody is telling you: your body was already designed to make its own version of this appetite-suppressing hormone. However, most of us have stopped feeding the good bacteria responsible for producing it.In this episode, I'm breaking down the gut-centric theory of hunger, a fascinating concept that completely changed the way I think about appetite, cravings, and weight management. Plus, I'll share what happened when I personally experimented with a specific category of food for my upcoming book and experienced something I can only describe as... injecting GLP-1. Without the injection.On this episode, you'll learn: The science behind what GLP-1 actually is (1:40)The real reason you feel like you can't stop eating (and what you can do to stop it) (4:33)All about the jaw-dropping Chinese study where volunteers minimized their hunger (9:03)Exactly which foods crank up your body's natural GLP-1 production (11:29)The one food category I added to my own diet that had me leaving half my meal on the plate (13:43)For the full episode transcript and show notes: https://drgundry.com/how-to-boost-glp1-naturally Thank you to our sponsors! Check them out: Take your water to the next level with the AquaTru water purifier, go to aquatruwater.com and enter code “GUNDRY20” at checkout for 20% off.Get $20 off your first box plus a free year of protein, like sirloin or ribeye at ButcherBox.com/GUNDRY.Visit Juvent.com/GUNDRY and use code GUNDRY at checkout to get an extra $300 off your Juvent Micro-Impact Platform.Get a quote today at Progressive.com.Shop my new air filter, Homekind Total Air! Use code CLEANAIR for 10% off. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For millions of people living with obesity, weight loss drugs have been hailed as a game changer.They're known as GLP-1s but are more commonly known by their trade names: Ozempic, Wegovy and Mounjaro. So far they've only been made by two companies in Denmark and the US and they're pretty expensive. But now the patents for these drugs have expired in China and India, which means pharmaceutical companies in those countries can now make cheaper copies. India has a reputation as the "pharmacy of the world" because of its ability to turn expensive medicines into affordable mass-market products. The country is the world's largest supplier of generic medicines. Indian companies are already starting to produce and sell these weight loss drugs. So what impact will this have on the cost and supply of weight loss drugs in India and around the world? Archana Shukla, the BBC's India business correspondent in Mumbai, tells us why the expiry of the patents is such a big deal. And BBC Health correspondent James Gallagher explains how these drugs work. Instagram: @bbcwhatintheworld Email: whatintheworld@bbc.co.uk WhatsApp: +44 330 12 33 22 6 Presenter: Hannah Gelbart Producers: Chelsea Coates, Julia Ross-Roy and Benita Barden Video Producer: Baldeep Chahal Editor: Verity Wilde

Worried about gaining weight back after Ozempic, Wegovy, Mounjaro, or Zepbound?You're not alone. One of the biggest concerns people have during their GLP-1 journey is what happens after the weight loss phase—and how to actually maintain their results long-term.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down what sustainable weight maintenance really looks like, why maintaining weight loss is different from losing weight, and the habits that support long-term success.Because keeping weight off isn't about being perfect. It's about building routines that you can realistically maintain for years to come.We're covering:Why weight maintenance is different than weight lossCommon reasons people regain weight after losing itThe role of appetite, food noise, and long-term behavior changeWhy protein and strength training matter for maintenanceHow muscle supports long-term health and weight managementThe mindset shifts that make maintenance easierWhy all-or-nothing thinking keeps people stuckWhat successful long-term maintenance actually looks likeWhether you're currently taking Ozempic, Wegovy, Mounjaro, or Zepbound—or simply thinking ahead to the future—this episode will help you focus on the habits that support lasting results.

Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning. In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available. Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now! Episode Highlights: Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors Participants lost an average of 28.3% of their body weight in 80 weeks Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight Nearly everyone with prediabetes reversed it and returned to normal blood sugar Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity The highest discontinuation rate due to side effects was only 11%—mainly GI issues Retatrutide is not yet FDA approved but anticipated to launch early 2027 Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

It's Episode 20 of Season 24. Come celebrate the 15th Anniversary of The NoSleep Podcast!"Listen Closely" by Chris Hicks (Story starts around 00:08:40)Produced by Jeff ClementCast: Brie - Sarah Ruth Thomas, Janelle - Yenni Ann, Colonel Wayne - Peter Lewis, Automated Voice - Erin Lillis"Hole(d)" by Garrett Atkinson (Story starts around 00:25:45)TRIGGER WARNING!Produced by Claudius MooreCast: Colin - Atticus Jackson, Doug - Dan Zappulla, Heather - Rima Mycynek, Customer - David Cummings, Voice #1 - Jeff Clement, Voice #2 - Nichole Goodnight"New Admission, Room Six" by Arlo Vell (Story starts around 00:54:50)Produced by Phil MichalskiCast: Dr. Richard - Graham Rowat, Beatrice - Erin Lillis, Molly - Mary Murphy, Richie - Kyle Akers"Return to Shiver Creek" by Zalina Alvi (Story starts around 01:24:20)Produced by Jesse CornettCast: Maddy - Nikolle Doolin, Sarah - Wafiyyah White, Dan - Elie Hirschman"Marnie and Kyle in the Quick 'n' Now" by Jason Washer (Story starts around 02:01:50)TRIGGER WARNING!Produced by Phil MichalskiCast: Marnie - Linsay Rousseau, Kyle - Matthew Bradford, Jaime - Jesse CornettThis episode is sponsored by:Mint Mobile - Ditch overpriced wireless with Mint Mobileís deal and get premium wireless service for 15 bucks a month. Cut your wireless bill to 15 bucks a month at mintmobile.com/nosleepWeight Loss by Hims - Ready to reach your weight loss goals? Weight Loss by Hims and WegovyÆ. Get a personalized, affordable plan that gets you. Go to Hims.com/nosleep.Mars Men - With Mars Men, your natural ability to forge usable testosterone is optimized. Mars Men supports healthy T levels, energy, and stamina. Get 50% off for life plus free shipping and 3 free gifts at MenGoToMars.comClick here to learn more about The NoSleep Podcast teamClick here to learn more about Yenni Ann and the Story Sirens PodcastCheck out our NEW MERCH!Click here to learn more about the Crimewave at Sea 2.0 Cruise!Click here to get your Crimewave at Sea discount code and bonus event!Click here to learn more about Zalina AlviClick here to learn more about Jason Washer Executive Producer & Host: David CummingsMusical score composed by: Brandon Boone15th Anniversary illustration courtesy of Catriel TallaricoThe NoSleep Podcast is Human-made for Human Minds. No generative AI is used in any aspect of work.Audio program ©2026 - Creative Reason Media - The copyrights for each story are held by the respective authors. No duplication or reproduction of this audio program is permitted without the written consent of Creative Reason Media. No part of this audio program may be used or reproduced in any manner for the purpose of training artificial intelligence technologies or systems. All rights reserved.

GLP-1 drugs were first approved to treat diabetes and then caused a frenzy when it was discovered they were great for weight loss. But now scientists are discovering the drugs that have brand names including Ozempic and Mounjaro might offer so much more, from reducing the risk of heart attack to treating kidney disease. Today, Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University on how Ozempic is shaking things up, again. Featured:  Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University 

Welcome back to our weekend Cabral HouseCall shows!   This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track!   Check out today's questions:    Lisa: Hello Dr. Cabral, my 4 year old has Molluscum Contagiosum, I found an old podcast from 2017, episode 681, and wanted to know if you have any new updated information. They are mostly on her right side of her extremities. She had one for a while that would not heal for months. It was constantly red, inflammed and bleeding. I applied the recommended ACV and by the next day it was so much better. After about a week, its was gone. She still has the little "white head" pimples on her arm and leg. The protocol that was recommended then was for an 11 yr old and wanted to know if you suggest anything for her or have any new updated information. She does take a daily multi and a immune support that has echinacea and elderberry. Thank you for all your help in trying to keep the community healthy.        Bettina: Hello, Your knowledge has inspired me, thank you very much. I know someone who lost 25–30 kg with Wegovy and now feels and look great despite eating ultra-processed foods, drinking Pepsi Max and occasional energy drinks. I try to follow your health principles—daily smoothie with DNS, whole foods, supplements, and mainly water. Still, I've been diagnosed with lipedema (stage 1–2), have fluid retention in my legs, excess weight, and daily pain (knees, heel spur, and foot pain). At times, I feel tempted to try Wegovy and care less, as I seem to struggle more while having limited time and money for treatments and supplements. Why is there such a difference between people, and where should I start?       Sonny: Hi Dr. Cabral, thank you for all your help and education over the years. My name is Sonny, I'm an IHP Level 2 practitioner from the UK writing on behalf of my 68-year-old mum. For several years she has experienced chronic coughing whenever eating solid meals, but not with liquids or smoothies. She also gets reflux and coughing when lying flat at night or during Pilates exercises. From an IHP2 lens I suspected low stomach acid, so we trialled ACV before meals along with digestive enzymes and HCL + pepsin. For the first time in years she ate without coughing, which felt like a major breakthrough. However, lying flat still triggers symptoms, making me wonder about LPR or a hiatal hernia alongside hypochlorhydria. What would you suggest next please?       Tricia: Hi Dr. Cabral -- my question is about your advance collagen support. Is it hydrolyzed? I have a lot of issues with my tendons and do get hip bursitis. I also take a good day or two to recover when I do exercise. I can do back to back days and trust me I'm not lifting heavy anymore now that I'm in my 50's. I have spine issues as well. Would your collagen support be good for my tendons or it mostly for hair, skin and nails? It seems that I stay in PT and do exercise but I can't seem to get my muscle imbalances under control especially as I age. Always love your advice. You are amazing! Thank you!      Tricia: Hi - yes me again. This question is for my 65 year old sister. She was recently under a lot of stress at home with her child leaving the country to live and her husband diagnosed with cancer. The stress was hard on her. Now pills are getting stuck in her esophagus. She went to the dr and they did all the tests & procedures. All was ok. They did stretch her esophagus a bit. We believe she is in the early stage of acid reflux. We want to heal it before it gets worse. I told her to absolutely not take the purple pill! What would you recommend? She can't afford the tests right now (due to hubby) and since she can't swallow pills easily she is at a loss. Do you have any advice or guidance for someone who can't take pills? Can she do CBO Pro and open up pills? Help       Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!    - - - Show Notes and Resources: StephenCabral.com/3781 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Morse code transcription: vvv vvv Jilted Swansea bride Kayley Stead who still held wedding gets engaged England midfielder Declan Rice on his sunburn and World Cup heat Child rape sentence reignites scrutiny of UK high street mini marts Weight loss drug Wegovy to be available in pill form in UK for first time El Ni o has begun, scientists say, and could bring record heat Mis Teeq on reuniting, UK garage and Alesha Dixons ad libs Mean Girls Lead actress scared after disorder as Belfast shows cancelled Hidden house farmer hits back after conviction Cramlington crash police officer, 19, dies in hospital Brother and sister guilty of attacking teenage girls in Dundee

Semaglutide. Tirzepatide. Retatrutide. The peptide conversation has taken over every gym, group chat, and social media feed. But the part about muscle loss, osteopenia, and what the gray market is actually selling you? That part is getting buried. Chalene Johnson sits down with Adam Schafer, co-host of Mind Pump, one of the top fitness podcasts in the world with nearly half a billion downloads. Adam spent three and a half years running real test groups on GLP-1s including Ozempic and Wegovy. What he found changed his perspective entirely and he is not holding back. This conversation covers what is actually driving muscle and bone density loss in women over 40 and 50, why the scale and the mirror are lying about body composition, and what most women are getting wrong about building real strength in midlife. Plus the truth about the gray market and what those peptides may actually contain. This is the conversation the fitness industry is not having and it is one every woman over 40 needs to hear.

Amye is joined by Becca to “investigate” Steven McBee Senior. As you may remember, he pleaded guilty to fraud last year and has recently been sentenced. But what exactly did Steven McBee Senior do to land himself in jail for 24 months? We took to the internet to find out.Join us next week for our full coverage of The McBee Dynasty season 3!GET BONUS CONTENTUnlock ad-free episodes and exclusive bonus recaps by joining our community!Patreon: patreon.com/littlemissrecap (50% your first month through the month of June!Website: littlemissrecap.com/supportSUPPORT OUR SPONSORSFACTOR MEALS helps you save time in the kitchen with delicious, nutritious, chef-prepared cuisine. Meals come fully prepared and ready to eat in 2 minutes.Use our link and get 50% off your first box plus free shipping. Visit: www.factormeals.com/littlemiss50off and use code littlemiss50off.Hers now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy pill and the Wegovy pen. Visit forhers.com/LMR to get personalized, affordable care that gets you. OUR OTHER SHOWS & MERCHTrue Crime: Hear our latest documentary deep-dives on Murder She Watched at murdershewatchedpod.comShop Merch: Get your podcast gear at littlemissrecap.threadless.comCONNECT WITH USInstagram: @littlemissrecapFacebook Group: Little Miss Recap Podcast CommunityYouTube: Watch our recaps hereContact: Voicemail at littlemissrecap.com or email littlemissrecap@gmail.com Hosted on Acast. See acast.com/privacy for more information.

In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40

Timestamps : 00:00 — Intro — Welcome to the Holistic Kids Show 00:20 —  The Childhood Obesity Crisis: The Numbers 01:14 — Guest Introduction: Ashley Koff, RD 02:12 — Ashley's Personal Story & What Drove Her Mission 04:34 — Rethinking Weight: It's a Signal, Not a Sentence 05:15 — Introducing Your Best Shot & Weight Health 06:07 — Understanding Hormones: GLP-1, GIP, CCK & PYY Explained Simply 08:15 — How Gut Hormones Control Blood Sugar, Appetite & Bone Health 10:16 — The Gut-Hormone Connection: Why Your Microbiome Matters 11:05 — Can Kids Take GLP-1 Hormones? 11:25 — Ozempic, Wegovy & GLP-1 Medications Explained 13:40 — GLP-1 Medications Approved for Kids 10+ — What Parents Must Know 15:28 — 3 Daily Habits to Naturally Balance Your Hormones 17:21 — Habit #2: Eat Like a Race Car — Fueling at the Right Times 18:04 — Habit #3: Move After Every Meal — Why 7 Minutes Matters 22:03 — "Better, Not Perfect" — What That Really Means for Teens 25:00 — The One Nutrition Rule Every Kid Should Know 29:49 — Where to Find Ashley Koff & Her Resources One in five US children lives with obesity — but are we asking the right questions? In this powerful episode, the Holistic Kids crew sits down with Ashley Koff, RD, USA Today bestselling author of Your Best Shot and a leading weight health practitioner with over 25 years of experience. Ashley flips the script on how we talk about weight with kids — moving away from diets, BMI, and body shame, and toward understanding what the body is actually telling us. She explains how hormones like GLP-1, GIP, and PYY are made in the gut lining, why antibiotics and medications can disrupt them for years, and what that means for growing bodies. The conversation also tackles the rising use of GLP-1 medications (like Ozempic and Wegovy) in kids as young as 10 — what the research says, what parents and teens should know, and why these medications are a tool, not a solution on their own. In this episode, you'll learn: Why weight is a signal, not a sentence What GLP-1, GIP, and gut hormones actually do — explained simply How antibiotics and medications affect your hormones for years The truth about GLP-1 medications for kids and teens 3 daily habits to naturally support hormone balance Why BMI is a flawed measure — and what to look at instead The "race car" nutrition approach that keeps your body running better What "better, not perfect" really means for teenagers Guest: Ashley Koff, RD — Founder of The Better Nutrition Program, author of Your Best Shot, recognized by CNN as one of the Top 100 Health Makers.

Could eating late at night be hurting your gut health? Are prebiotic and probiotic sodas actually good for your microbiome? And what do GLP-1 weight loss drugs such as Ozempic and Wegovy mean for digestion, constipation, and gut bacteria? Dr. Will Bulsiewicz joins Chuck Carroll on The Exam Room Podcast to answer the most Googled gut health questions from listeners.

Amye is joined by Kyla to discuss Hollywood Demons S2:EP5 Surviving 16 & PregnantExpecting teens met unexpected backlash after appearing on the controversial MTV show, "16 and Pregnant"; sixteen years since the show's debut, cast members open up about the struggles they faced in its wake, including homelessness, addiction, an FBI raid, and insinuations of murder.GET BONUS CONTENTUnlock ad-free episodes and exclusive bonus recaps by joining our community!Patreon: patreon.com/littlemissrecap (50% your first month through the month of June!Website: littlemissrecap.com/supportSUPPORT OUR SPONSORSFACTOR MEALS helps you save time in the kitchen with delicious, nutritious, chef-prepared cuisine. Meals come fully prepared and ready to eat in 2 minutes.Use our link and get 50% off your first box plus free shipping. Visit: www.factormeals.com/littlemiss50off and use code littlemiss50off.Hers now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy pill and the Wegovy pen. Visit forhers.com/LMR to get personalized, affordable care that gets you. OUR OTHER SHOWS & MERCHTrue Crime: Hear our latest documentary deep-dives on Murder She Watched at murdershewatchedpod.comShop Merch: Get your podcast gear at littlemissrecap.threadless.comCONNECT WITH USInstagram: @littlemissrecapFacebook Group: Little Miss Recap Podcast CommunityYouTube: Watch our recaps hereContact: Voicemail at littlemissrecap.com or email littlemissrecap@gmail.com Hosted on Acast. See acast.com/privacy for more information.

90 Day Fiance S12:EP5 & The Last Resort S3:EP2Amye is joined by Amanda to discuss 90 Day Fiance S12:EP5 & The Last Resort S3:EP2The Last Resort starts at 48 mins. 90 Day Fiance:Something Old, Something New - Rasit offends Mallorie's ex-fling Brandon at his USA-themed welcome party. Edward learns Marissa's strict house rules and meets her ex-husband. Debby and Mido struggle to make amends. Josh isn't impressed with Catie and his new apartment. Ashia heads to Nigeria to reunite with Maxwell.Last Resort:Last Crown Standing - Shekinah and Sarper remain distant. Jenny reveals why she doesn't trust Sumit. Rebecca and Zied unravel over control. Kara and Guillermo face painful truths. Patrick and Thais disagree on how to spend their time. Pao questions her future with Russ.GET BONUS CONTENTUnlock ad-free episodes and exclusive bonus recaps by joining our community!Patreon: patreon.com/littlemissrecap (50% your first month through the month of June!Website: littlemissrecap.com/supportSUPPORT OUR SPONSORSFACTOR MEALS helps you save time in the kitchen with delicious, nutritious, chef-prepared cuisine. Meals come fully prepared and ready to eat in 2 minutes.Use our link and get 50% off your first box plus free shipping. Visit: www.factormeals.com/littlemiss50off and use code littlemiss50off.Hers now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy pill and the Wegovy pen. Visit forhers.com/LMR to get personalized, affordable care that gets you.OUR OTHER SHOWS & MERCHTrue Crime: Hear our latest documentary deep-dives on Murder She Watched at murdershewatchedpod.comShop Merch: Get your podcast gear at littlemissrecap.threadless.comCONNECT WITH USInstagram: @littlemissrecapFacebook Group: Little Miss Recap Podcast CommunityYouTube: Watch our recaps hereContact: Voicemail at littlemissrecap.com or email littlemissrecap@gmail.com Hosted on Acast. See acast.com/privacy for more information.

SLC is officially one of America's "stickiest" downtowns — we break down the new Gensler study and what it means (plus where Denver landed). The flesh-eating screwworm just crossed into Texas for the first time in 60 years. Utah officials are watching closely. The Utah prison system is saving taxpayer dollars with a complete healthcare redesign — but it raises some interesting questions. We dive in with the Morality Police. In Health Class, a new study says Ozempic and Wegovy may slow biological aging by 9%.  Ethan and Alex put their friendship to the test after reading about the red flags that suggest a friendship isn't worth saving. Plus: a 17-year-old drowns at Bear Lake and trauma season is here. Why do Americans hate sharing bathrooms? Scammers are using AI images of a missing Utah cat to demand thousands, a couple is charged for hoarding hundreds of "street rats," and a man lost $30K because squirrels love plant-based car parts. Plus, Uber drops its wildest lost-and-found list ever (dentures, a Donny Osmond photo, 420 donuts).  AI Question of the Day: What's the best way to handle pet deaths with kids?   Stream KSL NewsRadio LIVE: kslnewsradio.com/listen Watch on YouTube: https://www.youtube.com/@KSLBrightside Facebook: https://www.facebook.com/KSLBrightside Instagram: https://www.instagram.com/KSL_Brightside TikTok: https://www.tiktok.com/@ksl.brightside

On today's show Kristian and Winston talk about Masters of the Universe, Star Wars, Jason Statham, The next $1b movie, Doomsday, Spider-Man, The Odyssey, update everyone on the Schomedown Vault and more!   #mastersoftheuniverse #doomsday #avengersdoomsday #starwars #spiderman #marvel #theodyssey  00:00 Show Begins & Opening Banter 05:42 He-Man vs Scary Movie 21:20 Liquid IV & Hims 24:48 Star Wars Reactions 30:52 Will The Odyssey Make $1Billion Dollars?  What will? 49:14 Statham Stole My Bike? 50:58 Schmoedown Vault Update 52:28 Q&A 2:13:34 Superchat War SPONSORS: LIQUID IV: Go to https://www.LIQUIDIV.com and get 20% off your first purchase with code KRISTIAN at checkout  RUGIET: Head to https://www.rugiet.com/KRISTIAN and get 15% off your ED treatment. HIMS:  Ready to reach your goals? Visit https://www.hims.com/KRISTIAN to get a personalized, affordable plan that gets you. - Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hims is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A.S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.hims.com

The grilling continues as Whitney tangles once again with her comedic shadow-self, Kevin Christy Tickets for The Big Baby Tour https://www.whitneycummings.com SHOP: https://whitneycummings.com/index.html#store Thank you to our sponsors! CHUBBIES #ad Your new wardrobe awaits! Get 20% OFF @chubbies with the code WHITNEY at https://www.chubbiesshorts.com/WHITNEY #chubbiespod iRestore #ad Unlock your best hair & skin with @iRestorelaser and HUGE savings on iRESTORE with code WHITNEY at https://irestore.com/WHITNEY! #irestorepod HERS #ad Ready to reach your goals? Visit https://www.forhers.com/whitney to get personalized, affordable care that gets you. Weight Loss by Hers is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.forhers.com. RUGGABLE #ad Refresh your home at https://www.ruggable.com. Get 10% off your first order, sitewide, with promo code WHITNEY at https://www.ruggable.com.

It's Episode 18 of Season 24. Enter the dark waters of the Cape Fear River as we present tales about perilous pairs."Worms" by Nick Porisch (Story starts around 00:07:05)TRIGGER WARNING!Produced by Phil MichalskiCast: Evie - Sarah Ruth Thomas, James - Jeff Clement, Kid - Matthew Bradford, Driver - Graham Rowat"One in a Million" by D.H.Parish (Story starts around 00:31:20)Produced by Phil MichalskiCast: Narrator - Dan Zappulla, Courtney - Mary Murphy, Jeff - Atticus Jackson"I'm a state patrol officer. I know what really happens between mile markers 189 and 206." by Jamie Frances Janazian (Story starts around 00:52:30)Produced by Claudius MooreCast: Zac - Mike DelGaudio, Marta - Linsay Rousseau"Silo" by Erin Michelitsch (Story starts around 01:12:30)Produced by Jeff ClementCast: Narrator - Erin Lillis, Julie - Linsay Rousseau, David - Graham Rowat"The Skull on the Headland" by Simon Bleaken (Story starts around 01:28:35)TRIGGER WARNING!Produced by Jesse CornettCast: Narrator - David Ault, Carolyn - Ash Millman, Rebecca - Erika Sanderson, Stephen - Jake Benson, Lauren - Penny Scott-AndrewsThis episode is sponsored by:Storyworth - Create collaborative books to celebrate milestones, collect stories and photos from trips, gather recipes, and preserve all of lifeís memories. Head to storyworth.com/nosleep to save up to $20 and make memories that will last a lifetime.Boll & Branch - Discover your best sleep with bedding from Boll and Branch. Find the perfect balance of comfort, breathability, and craftsmanship. Get 20% off your first order, plus free shipping during the Memorial Day Sale at BollAndBranch.com/nosleep with code nosleep.Weight Loss by Hims - Ready to reach your weight loss goals? Weight Loss by Hims and WegovyÆ. Get a personalized, affordable plan that gets you. Go to Hims.com/nosleep.Click here to learn more about The NoSleep Podcast teamClick here to learn more about this episode's host: David AultCheck out our NEW MERCH!Click here to learn more about the Crimewave at Sea 2.0 Cruise!Click here to get your Crimewave at Sea discount code and bonus event!Click here to learn more about D.H.ParishClick here to learn more about Erin Michelitsch Executive Producer & Host: David CummingsMusical score composed by: Brandon Boone"The Skull on the Headland" illustration courtesy of Alia SynesthesiaThe NoSleep Podcast is Human-made for Human Minds. No generative AI is used in any aspect of work.Audio program ©2026 - Creative Reason Media - The copyrights for each story are held by the respective authors. No duplication or reproduction of this audio program is permitted without the written consent of Creative Reason Media. No part of this audio program may be used or reproduced in any manner for the purpose of training artificial intelligence technologies or systems. All rights reserved.